Medication info

Empagliflozin and Sitagliptin Sustained Release Tablets 12.5/50/750 mg (Empagliflozin, Sitagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›757.5mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Brown, double convex, oval-shaped sustained release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501988 · Approved 2025.07.30

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily in the evening with a meal. If the metformin hydrochloride dose needs to be adjusted, increase the dose gradually. Patients taking the 25/100/1000 mg or 10/100/1000 mg extended-release tablet should take 1 tablet once daily. Patients taking the 12.5/50/750 mg or 5/50/750 mg extended-release tablet should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should provide empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current metformin hydrochloride dose or a therapeutically equivalent dose. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be based on the previous doses of each component. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Because changes may cause alterations in glycemic control, any changes in treatment for patients with type 2 diabetes should be made under careful monitoring. Special populations Patients with renal impairment The efficacy and safety of this medicine vary according to renal function, and dose adjustment according to renal function is required. Therefore, assessment of renal function is recommended before treatment and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes in conjunction with dietary and exercise therapy. The combination of Empagliflozin, Sitagliptin, and Metformin helps effectively lower blood sugar levels. This contributes to improving the condition of patients who have difficulty managing blood sugar.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily in the evening with a meal. If the metformin hydrochloride dose needs to be adjusted, increase the dose gradually. Patients taking the 25/100/1000 mg or 10/100/1000 mg extended-release tablet should take 1 tablet once daily. Patients taking the 12.5/50/750 mg or 5/50/750 mg extended-release tablet should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the initial dose of this medicine should provide empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current metformin hydrochloride dose or a therapeutically equivalent dose. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be based on the previous doses of each component. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Because changes may cause alterations in glycemic control, any changes in treatment for patients with type 2 diabetes should be made under careful monitoring. Special populations Patients with renal impairment The efficacy and safety of this medicine vary according to renal function, and dose adjustment according to renal function is required. Therefore, assessment of renal function is recommended before treatment and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) falls below 45 ml/min or estimated glomerular filtration rate (eGFR) falls below 45 ml/min/1.73m2, this medicine must be discontinued immediately.

Precautions

This medication is used for diabetes treatment and contains three ingredients. There are several precautions to be aware of when taking this medication. First, the Sitagliptin component may rarely cause severe allergic reactions. If symptoms like skin rash, difficulty breathing, or swelling of the face or lips occur, discontinue use immediately and consult a doctor. Second, Sitagliptin may cause acute pancreatitis, an inflammation of the pancreas, so if abdominal pain, vomiting, or loss of appetite occur while taking it, promptly inform a healthcare provider. Third, the Metformin component may rarely lead to a serious condition called lactic acidosis. This condition can be accompanied by symptoms such as vomiting, abdominal pain, muscle pain, difficulty breathing, and fatigue. Patients with impaired kidney function, severe infections, dehydration, or heart failure should be particularly cautious. Fourth, this medication is not recommended for patients with type 1 diabetes, acute metabolic acidosis, severe renal impairment, or acute heart failure. Fifth, the use of this medication should be temporarily interrupted before and after surgery or during conditions of severe infection or dehydration, and should be restarted after recovery. Sixth, dosage adjustments may be necessary based on kidney function, and regular kidney function tests are recommended. Particularly elderly patients or those with reduced kidney function should undergo more frequent testing. Seventh, this medication may cause hypoglycemia, so blood sugar levels should be closely monitored, especially when taken with insulin or sulfonylurea medications. Eighth, during the use of this medication, genital infections or urinary tract infections may occur, so immediate treatment should be sought if symptoms appear. Ninth, symptoms of low blood pressure or dehydration may occur due to reduced fluid volume, so elderly patients or those with low blood pressure should exercise caution and discontinue use during dehydration. Tenth, this medication is not recommended for patients with liver dysfunction, and healthcare providers should be informed immediately if symptoms of liver dysfunction arise. Finally, this medication should be swallowed whole and not chewed or crushed. The tablet shell may be excreted in the stool, but this is a normal occurrence. Regular blood tests and health assessments should be conducted to ensure safe treatment while taking this medication.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin diseases
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • dyspepsia
  • abdominal pain
Show 146 more
  • hyperglycemia
  • inadequately controlled diabetes
  • genital pruritus
  • vulvar pruritus
  • vaginal infections
  • weight loss
  • thirst
  • rash
  • urticaria
  • angioedema
  • hypovolemia
  • increased urination
  • urinary retention
  • interstitial nephritis
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • vulvovaginal candidiasis
  • balanitis
  • urinary tract infections
  • perineal necrosis
  • ketoacidosis
  • urosepticemia
  • pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • urolithiasis
  • acute kidney injury
  • cervicitis
  • hyponatremia
  • diabetic foot
  • lumbosacral pain
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • macular retinal detachment
  • limb injuries
  • road traffic accidents
  • splenic injury
  • sternal fractures
  • angina
  • Prinzmetal angina
  • coronary artery disease
  • deep vein thrombosis
  • benign neoplasm of the ampulla of Vater
  • benign ovarian tumors
  • bladder cancer
  • gastric cancer
  • pancreatic adenocarcinoma
  • colorectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • anxiety
  • depression
  • sleep disorders
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • constipation
  • diarrhea
  • dyspepsia
  • gastritis
  • upper respiratory tract infections
  • herpes zoster
  • vertigo
  • chest discomfort
  • chest pain
  • asthenia
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • conjunctival congestion
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin lacerations
  • bruising
  • rib fractures
  • concussion
  • corneal abrasion
  • falls
  • hand fractures
  • iliolumbar ligament syndrome
  • open eye injuries
  • pelvic fractures
  • unstable angina
  • arteriosclerosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • erectile dysfunction
  • acute renal failure
  • severe and disabling arthralgia
  • blistering-like pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius to safely preserve the medication's efficacy.

Appearance and packaging

Appearance

Brown, double convex, oval-shaped sustained release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.